Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In a bid to enhance its research services offerings, Sigma-Aldrich has acquired Pharmorphix Limited, a privately held firm based in Cambridge, UK that offers solid-form research services to the global pharmaceutical and biotech markets.
Subscribe to our email newsletter
Pharmorphix provides solid form research services. These services are sold to a large number of pharmaceutical and biotech customers that require information on the solid state of therapeutics to support regulatory and intellectual property submissions.
The addition of Pharmorphix will broaden the customer base of SAFC Pharma, the pharmaceuticals segment of SAFC, Sigma-Aldrich’s custom manufacturing group. The purchase will also enhance SAFC Pharma’s technology services offering.
The acquisition of Pharmorphix, which had sales of roughly $5 million over the past 12 months, will not have a material impact on Sigma-Aldrich’s sales. The acquisition is expected to help the company achieve its growth goals over the next several years and is expected to be neutral to mildly accretive to earnings in 2006, with no initial charges.
Pharmorphix is the second company this year to be integrated within the SAFC organization, following the May 2006 acquisition of Iropharm, a commercial-scale chemical synthesis manufacturing site in Arklow, Ireland.
“Recently-published FDA guidelines concerning specification of active pharmaceutical ingredient (API) solid form make the services provided by firms such as Pharmorphix crucial to the pharmaceutical industry,” commented SAFC president, Frank Wicks. “In addition, better understanding and characterization of solid form provides valuable intellectual property that can be used to extend the patent life of new therapeutics.”